Recombinant Human FOLH1 Protein, His (Fc)-Avi-tagged

• Cat.No.: FOLH1-931H
• Product Overview: Recombinant Human FOLH1 with His (Fc)-Avi tag was expressed and purified

Specification

• Source: HEK293
• Species: Human
• Tag: His&Fc&Avi
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: ≥85% by SDS-PAGE
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: FOLH1 folate hydrolase 1 [ Homo sapiens (human) ]
• Official Symbol: FOLH1
• Synonyms: PSM; FGCP; FOLH; GCP2; PSMA; mGCP; GCPII; NAALAD1
• Gene ID: 2346
• mRNA Refseq: NM_004476.3
• Protein Refseq: NP_004467.1
• MIM: 600934
• UniProt ID: Q04609

Reviews

09/05/2019

It has been shown to play a crucial role in multiple cellular processes, making it highly valuable for investigations into cell signaling, inflammation, and immune responses.

01/28/2018

Incorporating the FOLH1 protein into your research will not only meet but exceed your expectations, enabling you to advance your scientific discoveries with confidence.

06/06/2016

Researchers can leverage the unique properties of the FOLH1 protein to gain insights into its biological functions and its impact on disease mechanisms.

Q&As

What advancements have been made in FOLH1-targeted therapies recently?

New radioligands and imaging agents with enhanced specificity and reduced off-target effects are being developed for more effective treatment.

How does targeting FOLH1 impact treatment precision?

Targeting FOLH1 helps deliver treatments directly to cancer cells, minimizing damage to healthy tissues, thus improving treatment precision.

Are there other potential applications of FOLH1 beyond prostate cancer?

Yes, research suggests potential roles in imaging and therapy for other cancers expressing FOLH1, such as renal cell carcinoma and certain types of gliomas.

Can FOLH1 be used for early cancer detection?

Yes, FOLH1-based imaging techniques show promise in detecting cancer at early stages, aiding in timely intervention and improved outcomes.

Are there ongoing clinical trials exploring FOLH1's applications?

Yes, numerous trials investigate FOLH1-targeted imaging and therapies in various cancers, aiming to expand its clinical utility.